Skip to main content

Table 2 Multivariate analysis by virological outcome (VL < 400 copies/ml)

From: An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Variable Adjusted OR (95% CI) P value
Sex
 Female Reference .
 Male 0.63 (0.29–1.34) 0.233
Second-line regimen group
 ATV/r Reference .
 LPV/r 0.46 (0.20–1.03) 0.060
Age at switch to second-line, per 5 year increase 0.91 (0.76–1.10) 0.332
CD4 count cell/μl, at switch to second-line 0.99 (0.99–1.00) 0.468
Time (months) on first-line therapy 1.00 (0.99–1.02) 0.701
Time (years) after switch to viral load date 1.27 (0.95–1.68) 0.103
  1. Note: Adjusted for matching using propensity scores: